Your kidney cancer research in basic science, translational medicine and clinical medicine is important. And you have a choice when you select a journal in which to publish your results. We invite you to submit your manuscript to Kidney Cancer, now Gold Open Access!

Since its launch in 2017, Kidney Cancer has been going from strength to strength. Check out the very latest articles in the journal by clicking on the banner image to go straight to the content!

Aims and Scope

Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the kidney. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that will expedite our fundamental understanding and improve treatment of tumors of the kidney.

Latest Articles

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time? - Open Access

Clinical Trials Corner: Raising the SABR to Renal Cell Carcinoma - Open Access

Efficacy of Therapy vs Surveillance in Patients with Resected Early-Stage Intermediate to High-Risk Renal Cell Carcinoma - Open Access

Clinical Trials Corner

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Untreated Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment of Patients with Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (pRCC)

Welcome to Kidney Cancer

Editorial Board

Primo N. Lara Jr, MD

University of California Davis Comprehensive Cancer Center
Sacramento, CA, USA

Email: kca@iospress.com

Peter Mulders, MD, PhD

Radboud UMC Nijmegen,The Netherlands

Email: kca@iospress.com

Submission Guidelines

SUBMIT YOUR MANUSCRIPT HERE

SUBMISSION OF MANUSCRIPTS:

AUTHOR INSTRUCTIONS

Authors are requested to submit their manuscript electronically to the online submission system msTracker. Note that the manuscript should be uploaded as one file with tables and figures included.

Tweets

1 year 11 months ago

Kidney Cancer

@KCA_Journal

📢 Call for Papers‼️ We invite you to submit your manuscript to, One of the world's leading journals in GU Oncology,… https://t.co/i2disFDjnS

1 year 11 months ago

Kidney Cancer

@KCA_Journal

RT @DrChoueiri: Thank you @TIME magazine for highlighting our journey with @CJSTRAV3 our dear patient, battling Kidney Cancer… https://t.co/Ta2tTrPH79

Clinical Trials Corner

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Untreated Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment of Patients with Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (pRCC)

A Phase II Randomized Trial of Cabozantinib (NSC#761968) With or Without Atezolizumab (NSC#783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)

No front page content has been created yet.

Search form

Welcome to Kidney Cancer

Editorial Board

Submission Guidelines

Tweets

Clinical Trials Corner